よむ、つかう、まなぶ。
資料２－２ ［1.3MB］ (13 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_38855.html |
| 出典情報 | 薬事・食品衛生審議会 薬事分科会医薬品等安全対策部会安全対策調査会（令和5年度第15回 3／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
引用文献
Brooks DJ, et al. J Neurol Neurosurg Psychiatry. 2003;74:1071-1079. Entacapone is beneficial in
both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomized, placebo
controlled, double blind, six month study.
Delea TE et al. Current Medical Research and Opinion 2010: 26:7, 1543-1552, DOI:
10.1185/03007991003780628Adherence with levodopa/carbidopa/entacapone versus
levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson’s disease.
EMA/409815/2020 Rev.14 Questions and answers for marketing authorisation
holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004
referral on nitrosamine impurities in human medicinal products
EMEA/H/A-31/1471 Assessment report Referral under Article 31 of Directive 2001/83/EC
angiotensin-II-receptor antagonists (sartans) contAI ning a tetrazole group
Ferreira JJ et al. European Journal of Neurology 2013, 20: 5–15. Summary of the
recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease
ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit
potential carcinogenic risk
Kuoppamäki et al. Acta Neurol Scand 2014: 130: 239–247. Pooled analysis of phase III with
entacapone in Parkinson’s disease
Mizuno Y, et al. Movement Disorders 2007; 22 (1): 75-80. Placebo-controlled, double-blind dosefinding study of entacapone in fluctuating Parkinsonian patients.
Myllylä V et al. Acta Neurol Scand 2006: 114: 181–186 DOI: 10.1111/j.16000404.2006.00703. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD
patients experiencing wearing-off (Simcom Study).
Parkinson Study Group. Ann Neurol. 1997;42:747-755. Entacapone Improves Motor
Fluctuations in Levodopa-Treated Parkinson’s Disease Patients.
Poewe WH, et al. Acta Neurol Scand. 2002;105:245-255. Efficacy and safety of entacapone in
Parkinson’s disease patients with suboptimal Levodopa response: a 6-month randomized placebocontrolled double-blind study in Germany and Austria (Celomen study).
Rinne UK, et al. Neurology. 1998;51:1309-1314. Entacapone enhances the response to
levodopa AI n parkinsonian patients with motor fluctuations.
Stacy M et al. Clin Neuropharmacol 2006, 29: 312-321. End-of-dose Wearing-Off in
Parkinson Disease: A 9-Question Survey Assessment
5
-13-
Brooks DJ, et al. J Neurol Neurosurg Psychiatry. 2003;74:1071-1079. Entacapone is beneficial in
both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomized, placebo
controlled, double blind, six month study.
Delea TE et al. Current Medical Research and Opinion 2010: 26:7, 1543-1552, DOI:
10.1185/03007991003780628Adherence with levodopa/carbidopa/entacapone versus
levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson’s disease.
EMA/409815/2020 Rev.14 Questions and answers for marketing authorisation
holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004
referral on nitrosamine impurities in human medicinal products
EMEA/H/A-31/1471 Assessment report Referral under Article 31 of Directive 2001/83/EC
angiotensin-II-receptor antagonists (sartans) contAI ning a tetrazole group
Ferreira JJ et al. European Journal of Neurology 2013, 20: 5–15. Summary of the
recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease
ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit
potential carcinogenic risk
Kuoppamäki et al. Acta Neurol Scand 2014: 130: 239–247. Pooled analysis of phase III with
entacapone in Parkinson’s disease
Mizuno Y, et al. Movement Disorders 2007; 22 (1): 75-80. Placebo-controlled, double-blind dosefinding study of entacapone in fluctuating Parkinsonian patients.
Myllylä V et al. Acta Neurol Scand 2006: 114: 181–186 DOI: 10.1111/j.16000404.2006.00703. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD
patients experiencing wearing-off (Simcom Study).
Parkinson Study Group. Ann Neurol. 1997;42:747-755. Entacapone Improves Motor
Fluctuations in Levodopa-Treated Parkinson’s Disease Patients.
Poewe WH, et al. Acta Neurol Scand. 2002;105:245-255. Efficacy and safety of entacapone in
Parkinson’s disease patients with suboptimal Levodopa response: a 6-month randomized placebocontrolled double-blind study in Germany and Austria (Celomen study).
Rinne UK, et al. Neurology. 1998;51:1309-1314. Entacapone enhances the response to
levodopa AI n parkinsonian patients with motor fluctuations.
Stacy M et al. Clin Neuropharmacol 2006, 29: 312-321. End-of-dose Wearing-Off in
Parkinson Disease: A 9-Question Survey Assessment
5
-13-